Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 15 | 2022 | 328 | 1.470 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 15 | 2022 | 402 | 0.870 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2010 | 50 | 0.690 |
Why?
|
| Hodgkin Disease | 6 | 2010 | 55 | 0.680 |
Why?
|
| Stem Cell Transplantation | 8 | 2022 | 75 | 0.600 |
Why?
|
| Transplantation, Autologous | 18 | 2022 | 119 | 0.520 |
Why?
|
| Multiple Myeloma | 7 | 2022 | 325 | 0.430 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 4 | 2008 | 65 | 0.390 |
Why?
|
| Lymphoma, B-Cell | 3 | 2005 | 59 | 0.330 |
Why?
|
| Transplantation Conditioning | 6 | 2010 | 98 | 0.280 |
Why?
|
| Fever | 2 | 2010 | 63 | 0.270 |
Why?
|
| Radiotherapy | 4 | 2010 | 61 | 0.270 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2006 | 4 | 0.260 |
Why?
|
| Interleukin-12 | 1 | 2006 | 123 | 0.240 |
Why?
|
| Prognosis | 11 | 2010 | 1597 | 0.240 |
Why?
|
| Interleukin-6 | 1 | 2006 | 309 | 0.230 |
Why?
|
| Melphalan | 4 | 2008 | 22 | 0.220 |
Why?
|
| Antibodies, Monoclonal | 2 | 2008 | 836 | 0.220 |
Why?
|
| Neoplasms, Second Primary | 2 | 2016 | 43 | 0.200 |
Why?
|
| Aged | 21 | 2016 | 13408 | 0.200 |
Why?
|
| Disease-Free Survival | 8 | 2010 | 228 | 0.190 |
Why?
|
| Middle Aged | 24 | 2012 | 16314 | 0.190 |
Why?
|
| Adult | 23 | 2012 | 15681 | 0.190 |
Why?
|
| Ifosfamide | 6 | 2010 | 8 | 0.170 |
Why?
|
| Etoposide | 6 | 2010 | 33 | 0.170 |
Why?
|
| Carboplatin | 6 | 2010 | 40 | 0.170 |
Why?
|
| Salvage Therapy | 5 | 2010 | 71 | 0.170 |
Why?
|
| Treatment Outcome | 13 | 2012 | 5283 | 0.170 |
Why?
|
| Neutropenia | 4 | 2010 | 62 | 0.160 |
Why?
|
| Recurrence | 7 | 2012 | 602 | 0.150 |
Why?
|
| Adolescent | 11 | 2010 | 5838 | 0.150 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 39 | 0.140 |
Why?
|
| Radium | 1 | 2016 | 1 | 0.140 |
Why?
|
| Disease Progression | 4 | 2009 | 1119 | 0.130 |
Why?
|
| Hematologic Neoplasms | 3 | 2012 | 44 | 0.130 |
Why?
|
| Combined Modality Therapy | 8 | 2010 | 354 | 0.130 |
Why?
|
| Survival Rate | 5 | 2008 | 801 | 0.120 |
Why?
|
| Dexamethasone | 3 | 2022 | 201 | 0.120 |
Why?
|
| Humans | 29 | 2022 | 59389 | 0.120 |
Why?
|
| Leukapheresis | 2 | 2012 | 8 | 0.120 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 167 | 0.110 |
Why?
|
| Antineoplastic Agents | 3 | 2008 | 628 | 0.100 |
Why?
|
| Blood Donors | 1 | 2012 | 22 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2009 | 554 | 0.100 |
Why?
|
| Male | 19 | 2016 | 27749 | 0.100 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2010 | 58 | 0.100 |
Why?
|
| Myeloablative Agonists | 2 | 2008 | 14 | 0.090 |
Why?
|
| Fibroblast Growth Factor 7 | 2 | 2008 | 3 | 0.090 |
Why?
|
| Remission Induction | 3 | 2008 | 137 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2012 | 218 | 0.090 |
Why?
|
| Thalidomide | 2 | 2007 | 32 | 0.090 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 65 | 0.090 |
Why?
|
| Hematologic Agents | 1 | 2010 | 3 | 0.080 |
Why?
|
| Female | 18 | 2012 | 30726 | 0.080 |
Why?
|
| Lymphocyte Depletion | 1 | 2010 | 99 | 0.080 |
Why?
|
| Follow-Up Studies | 7 | 2010 | 2338 | 0.080 |
Why?
|
| Razoxane | 1 | 2008 | 2 | 0.080 |
Why?
|
| Mesna | 1 | 2008 | 3 | 0.080 |
Why?
|
| Radiation-Protective Agents | 1 | 2008 | 8 | 0.080 |
Why?
|
| Amifostine | 1 | 2008 | 14 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2006 | 14 | 0.080 |
Why?
|
| Oligodendroglioma | 1 | 2008 | 7 | 0.080 |
Why?
|
| Astrocytoma | 1 | 2008 | 12 | 0.080 |
Why?
|
| Bortezomib | 2 | 2022 | 56 | 0.070 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2007 | 17 | 0.070 |
Why?
|
| Amyloidosis | 1 | 2007 | 62 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2008 | 446 | 0.070 |
Why?
|
| Young Adult | 6 | 2012 | 4272 | 0.060 |
Why?
|
| Carmustine | 1 | 2006 | 10 | 0.060 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 8 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2006 | 31 | 0.060 |
Why?
|
| Area Under Curve | 1 | 2006 | 141 | 0.060 |
Why?
|
| Germinal Center | 1 | 2005 | 38 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 267 | 0.060 |
Why?
|
| Stomatitis | 1 | 2004 | 7 | 0.060 |
Why?
|
| Brain Neoplasms | 1 | 2008 | 305 | 0.060 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 66 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 705 | 0.060 |
Why?
|
| Antigens, CD34 | 1 | 2004 | 54 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2004 | 57 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2012 | 448 | 0.050 |
Why?
|
| Plasmacytoma | 1 | 2003 | 9 | 0.050 |
Why?
|
| Rituximab | 1 | 2004 | 80 | 0.050 |
Why?
|
| Antigens, Neoplasm | 1 | 2003 | 133 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2006 | 1189 | 0.050 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 461 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2010 | 6071 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 1027 | 0.040 |
Why?
|
| Positron-Emission Tomography | 2 | 2010 | 200 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 1231 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2003 | 850 | 0.040 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2016 | 6 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2012 | 5119 | 0.030 |
Why?
|
| Incidence | 2 | 2010 | 1238 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 284 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 115 | 0.030 |
Why?
|
| Lung Diseases | 2 | 2008 | 170 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 3067 | 0.030 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2012 | 2 | 0.030 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2012 | 3 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2012 | 28 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 1507 | 0.030 |
Why?
|
| Pyrazines | 1 | 2012 | 33 | 0.030 |
Why?
|
| Haplotypes | 1 | 2012 | 115 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 163 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2010 | 2375 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 2012 | 172 | 0.020 |
Why?
|
| Family | 1 | 2012 | 229 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2012 | 526 | 0.020 |
Why?
|
| Leukopoiesis | 1 | 2010 | 2 | 0.020 |
Why?
|
| Filgrastim | 1 | 2010 | 6 | 0.020 |
Why?
|
| Transplantation Chimera | 1 | 2010 | 39 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2010 | 244 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 396 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 105 | 0.020 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2008 | 9 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 300 | 0.020 |
Why?
|
| Lomustine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Procarbazine | 1 | 2008 | 3 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2010 | 165 | 0.020 |
Why?
|
| Thiotepa | 1 | 2008 | 5 | 0.020 |
Why?
|
| Vincristine | 1 | 2008 | 25 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2008 | 12 | 0.020 |
Why?
|
| Busulfan | 1 | 2008 | 17 | 0.020 |
Why?
|
| Ileus | 1 | 2008 | 6 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2008 | 42 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2008 | 81 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2010 | 202 | 0.020 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2007 | 7 | 0.020 |
Why?
|
| Child | 2 | 2010 | 4189 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2010 | 689 | 0.020 |
Why?
|
| Radiation Injuries | 1 | 2008 | 62 | 0.020 |
Why?
|
| Risk Factors | 2 | 2010 | 4986 | 0.020 |
Why?
|
| Adjuvants, Immunologic | 1 | 2007 | 224 | 0.020 |
Why?
|
| Length of Stay | 1 | 2010 | 776 | 0.020 |
Why?
|
| Kidney | 1 | 2008 | 414 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2007 | 674 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2008 | 902 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2005 | 30 | 0.020 |
Why?
|
| Kidney Transplantation | 1 | 2008 | 313 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2006 | 97 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2005 | 11 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2004 | 24 | 0.010 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2004 | 27 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 1793 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 805 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 735 | 0.010 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2003 | 5 | 0.010 |
Why?
|
| Skin Neoplasms | 1 | 2008 | 397 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 715 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2004 | 179 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 249 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2003 | 151 | 0.010 |
Why?
|
| Neoplasm Proteins | 1 | 2003 | 278 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 847 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2003 | 297 | 0.010 |
Why?
|
| Age Factors | 1 | 2005 | 1504 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2007 | 1925 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 440 | 0.010 |
Why?
|